169 related articles for article (PubMed ID: 34690936)
1. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study.
Song E; Kim M; Park S; Park MJ; Kim JA; Roh E; Yu JH; Kim NH; Seo JA; Kim SG; Kim NH; Choi KM; Baik SH; Yoo HJ
Front Endocrinol (Lausanne); 2021; 12():761782. PubMed ID: 34690936
[TBL] [Abstract][Full Text] [Related]
2. Risk of Diabetes in Patients with Long-Standing Graves' Disease: A Longitudinal Study.
Song E; Koo MJ; Noh E; Hwang SY; Park MJ; Kim JA; Roh E; Choi KM; Baik SH; Cho GJ; Yoo HJ
Endocrinol Metab (Seoul); 2021 Dec; 36(6):1277-1286. PubMed ID: 34915605
[TBL] [Abstract][Full Text] [Related]
3. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
[No Abstract] [Full Text] [Related]
4. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.
Jin M; Jang A; Kim CA; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36826832
[TBL] [Abstract][Full Text] [Related]
6. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.
Okosieme OE; Taylor PN; Evans C; Thayer D; Chai A; Khan I; Draman MS; Tennant B; Geen J; Sayers A; French R; Lazarus JH; Premawardhana LD; Dayan CM
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):278-287. PubMed ID: 30827829
[TBL] [Abstract][Full Text] [Related]
7. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
[TBL] [Abstract][Full Text] [Related]
8. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study.
Brito JP; Payne S; Singh Ospina N; Rodriguez-Gutierrez R; Maraka S; Sangaralingham LR; Iñiguez-Ariza NM; Montori VM; Stan MN
Thyroid; 2020 Mar; 30(3):357-364. PubMed ID: 31973681
[No Abstract] [Full Text] [Related]
10. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
Chen DY; Chen TH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
[TBL] [Abstract][Full Text] [Related]
11. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?
Park S; Song E; Oh HS; Kim M; Jeon MJ; Kim WG; Kim TY; Shong YK; Kim DM; Kim WB
Endocrine; 2019 Aug; 65(2):348-356. PubMed ID: 31236779
[TBL] [Abstract][Full Text] [Related]
12. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
[TBL] [Abstract][Full Text] [Related]
13. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
14. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
[TBL] [Abstract][Full Text] [Related]
15. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
[No Abstract] [Full Text] [Related]
17. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
Glinoer D; de Nayer P; Bex M;
Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
[TBL] [Abstract][Full Text] [Related]
18. [Long-term follow up after antithyroid drug treatment in Graves' disease].
Wille T; Müller B; Noth D; Bürgi U; Diem P
Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience.
Azizi F
Thyroid; 2020 Oct; 30(10):1451-1457. PubMed ID: 32253999
[No Abstract] [Full Text] [Related]
20. Management of recurrent hyperthyroidism in patients with Graves' disease treated by subtotal thyroidectomy.
Sugino K; Mimura T; Ozaki O; Iwasaki H; Wada N; Matsumoto A; Ito K
J Endocrinol Invest; 1995 Jun; 18(6):415-9. PubMed ID: 7594234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
